Comparative Pharmacology
Head-to-head clinical analysis: DIASTAT versus VALTOCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIASTAT versus VALTOCO.
DIASTAT vs VALTOCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.
None Documented
None Documented
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Terminal elimination half-life: 15-17 hours (range 11-20 h) in adults; no dose adjustment for age or renal impairment is recommended, but clinical monitoring is prudent in hepatic impairment.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
Renal (70% as unchanged drug and metabolites, primarily glucuronide conjugate, with <2% as unchanged drug); biliary/fecal (30%)
Category C
Category C
Benzodiazepine Anticonvulsant
Benzodiazepine Anticonvulsant